30 closest matches · ranked by relevance
Bacteremia · Staphylococcus Aureus · Staphylococcus Aureus Bacteremia
Primary: Number of Participants With Treatment-Emergent Adverse Events (Safety and Tolerability) Following Multiple Doses of Intravenous AP-Sa02. — 17; 10; 6; 2 number of…
Staphylococcus Aureus Bacteremia
Primary: Number of Patients With or Without Overall Success at the Post-treatment Evaluation (PTE) Visit — 132; 136; 57; 62 Participants
Wound Infection Due to Staphylococcus Aureus · MRSA Infection of Postoperative Wound
Primary: Eradication of Staphylococcus Aureus (SA) Carriage at All 4 Body Sites Tested. — 13; 41 Participants
Bloodstream Infection · Sepsis Bacterial · MRSA Bacteremia
Primary: Time to Last Dose of Intravenous Vancomycin — 19.0; 12.5 time in hours
Bacteremia
Primary: Cure Rate — 207; 209 Participants
Staphylococcus Aureus Bacteremia · Staphylococcus Aureus Endocarditis
Primary: Incidence of Adverse Events [Safety and Tolerability] — 48; 30; 64; 40 Participants
Gram-Positive Bacterial Infections
Primary: Clinical Response (Cure, Failure, or Indeterminate) as Determined by the Investigator Based the Presence or Absence of Clinical Signs and Symptoms Associated With…
Staphylococcus Aureus Bacteremia
Primary: Number of Participants Who Experienced Dose-limiting Toxicities — 0; 0; 0; 0 participants
Staphylococcal Bacteraemia
Primary: Desirability of Outcome Ranking (DOOR) — 49; 49; 34; 37 Participants
Bacteremia · Fungemia · Bloodstream Infection
Primary: Duration of Antimicrobial Therapy (Hours) — 44; 42; 42; 8.2 hours — p=0.92
Pneumonia Due to Staphylococcus Aureus
Primary: Efficacy Endpoint: All-Cause Mortality by Day 28 — 1; 2; 2; 0 Participants
Staphylococcal Infection
Primary: Apparent Eradication of Nasal Carriage of SA — 9 participants
Skin Diseases, Infectious
Primary: Clinical Response at Test of Cure (TOC) — 86.2; 80.0; 0.0; 6.9 Percentage of participants
Open Reduction and Internal Fixation of Extremity Fractures
Primary: Number of Blood Samples With High Levels of Absorbance Via ELISA for Patients (Greater Than 1.5 Ratio Compared to Control Human Serum) — 48; 53 blood draw samples
Bloodstream Infection
Primary: Clinical Response Within 48 Hours — 28 Participants
Cutaneous Abscess
Primary: Recurrence of Cutaneous Abscess — 5; 7 Participants
MRSA Colonization
Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants
Atopic Dermatitis
Primary: Change in Eczema Area and Severity Index (EASI)Scores According to Location — -1.06; -0.57; -4.94; -0.88 Change in EASI Score
Hand Eczema · Foot Eczema
Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
Hodgkin Disease · Non-Hodgkin Lymphoma · Multiple Myeloma
Primary: Incidence of Clinically Significant Bacteremia — 3; 9 participants
Pneumonia
Primary: Time to 30-day Mortality — 15; 14 days
Sepsis
Primary: Mortality — 11 Participants
Bile Duct Stricture · Choledocholithiasis
Primary: Number of Patients With Bacteremia — 25; 20; 5; 10 Participants
Staphylococcal Infection
Primary: Efficacy Adjudication Committee (EAC) Assessment of Number of Participants With Clinical Success at Test of Cure (TOC) — 45; 16; 2 Participants
Staphylococcal Skin Infections · Abscesses · Furunculosis
Primary: Number of Index Patients Eradicated of S. Aureus Carriage - 1 Month After Performing Decolonization Measures — 39; 35 Participants — p=1.00
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Primary: Recurrence Rates of Abscesses — 4; 14 participants
Pharmacokinetics · Beta Lactam Adverse Reaction · Penicillin Allergy
Primary: Fraction of the Dosing Interval Over Which the Concentration of Unbound Drug is Greater Than the Minimum Inhibitory Concentration (fT>MIC) — 0.457; 0.429; 0.747; 0.417…
Methicillin Resistant Staphylococcus Aureus (MRSA)
Primary: Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population — 95; 81; 70; 93 Participants…
Bacteremia
Primary: Number of Participants With One or More Adverse Events (AEs) — 15; 6; 12; 9 Participants